Topic starter
Truffle session for autism
It is more common for people with autism spectrum disorders (ASD) truffles or psilocybin under supervision want to try because they feel they need to work on themselves. A recurring theme is often the emotional experience and how to deal with other people. For the session I have today in Amsterdam, it is primarily about connecting with the emotions.
Can truffles help connect with emotions in ASD?
In people on the autism spectrum, too, there appears to be a greater connection with emotions. What stands out during sessions with individuals with autism is that, especially at the beginning, they want to understand everything. At a certain point in the trip, confusion arises, and this creates resistance to the trip. As soon as the resistance to the confusion disappears, a connection with the emotions is often established.
A trip offers insights
An emotional journey for someone with autism often offers insights they otherwise would not have been able to arrive at. Nevertheless, they often make the emotions understandable and better understand the emotions of others through these insights. On a cognitive level, autistic individuals often become more empathetic by learning more nuances during their own emotional experiences. truffle session. Such an emotional journey can also foster greater self-understanding and enable them to view their own 'limitations' as an advantage or to accept them.
Posted : 21 February 2025 12:30
What studies have been conducted on psilocybin and autism?
1. The PSILAUT Study (2024)
- Title: The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin
- Authors: Whelan, T.P., Daly, E., Puts, N.A., Smith, P., Allison, C., et al.
- Summary:
This study investigates how psilocybin influences serotonin-related brain function in people with autism. The researchers are testing whether psilocybin alters sensory suppression and mismatch negativity (MMN), which may affect social and sensory processing in autistic individuals. This is the first direct clinical study to examine these effects.- Publication: BMC Psychiatry (2024)
- Link: Full study (PDF)
Background of the Research
Autism spectrum disorder is characterized by diverse differences in social interaction, communication, and sensory processing. Although the exact neurobiological causes remain largely unclear, various studies point to a crucial role of the serotonin system. The 5HT2A receptor appears to be particularly important in this regard, as it is involved in neuronal development and plasticity, among other things. Whereas previous studies have focused primarily on associations and correlations, this research goes a step further:
The goal is to directly measure how the brains of autistic and non-autistic adults differ in their response through a controlled change in serotonergic signaling—by means of low doses of psilocybin.
The PSILAUT Protocol: Structure and Methodology
The study is a case-control study with a pseudo-randomized, double-blind, placebo-controlled crossover design. In the study, approximately 30 autistic and 30 non-autistic adults are compared. Each participant visits the research facility three times, receiving either a placebo or a low dose of psilocybin (2 mg and 5 mg) each time. This makes it possible to identify individual and group-specific 'shifts' in brain function.
Study Structure in a Nutshell
| Order | Visit 1 | Visit 2 | Visit 3 |
|---|---|---|---|
| Option 1 | Placebo | 2 mg psilocybin | 5 mg psilocybin |
| Option 2 | 2 mg psilocybin | 5 mg psilocybin | Placebo |
| Option 3 | 2 mg psilocybin | Placebo | 5 mg psilocybin |
This design ensures that the lowest dose always precedes the higher dose, which promotes safety and the possibility of unblinding.
Multimodal Measurement Methods
To measure the 'shift' in brain function, a wide range of techniques is employed:
| Measurement method | What is measured | Technology/Method |
|---|---|---|
| fMRI | Resting-state connectivity and task-dependent activation | 3.0 Tesla MRI |
| EEG | Cortical oscillations, local circuit activity, and ERPs | 64-channel EEG |
| MRS | Levels of GABA and glutamate (Protein/Iodate balance) | Hadamard MRS (HERMES) |
| Psychophysical Tasks | Tactile and visual perception | Behavioral tasks |
| Questionnaires | Subjective effects (5D-ASC) and social/cognitive functions | Standardized tests |
In addition, subjective experiences are measured via the 5D-ASC questionnaire, and cognitive tasks (such as the 'Reading the Mind in the Eyes' test) are administered to further investigate social perception.
Expected Outcomes and Implications
The study focuses on the question of whether serotonergic action – and in particular the response via the 5HT2A receptor – differs in autistic adults from that in non-autistic individuals. It is expected that:
- The brain response at low doses of psilocybin in autistic individuals differs from those in controls.
- Individual differences can provide insight into serotonergic signaling regarding which subgroups might benefit from targeted pharmacological support.
- These insights can ultimately contribute to more personalized treatment options for autism.
Community and Stakeholder Engagement
Prior to the final design of the study, the team sought the opinion of the autistic community. A survey of 331 autistic adults revealed that the majority (41% very interested and 28% somewhat interested) were in favor of research into psilocybin, provided that safety aspects are handled carefully. This involvement underscores the importance of community engagement in research into new treatment options.
Conclusion
The PSILAUT study is an exciting step towards understanding the neurobiological basis of autism. Through a carefully designed, multimodal approach, researchers aim to directly measure how low doses of psilocybin affect brain function and the role the serotonin system plays in this process. These insights can not only contribute to our knowledge of autism but potentially also lead to the development of more personalized and effective treatment strategies.
Posted : 21 February 2025 12:43